EUVIMEDEUVIMED entdecken
Crossref

Pharmacokinetics of Levetiracetam Seizure Prophylaxis in Severe Traumatic Brain Injury

Sarah Schuman Harlan iD, Carolyn D Philpott, Shaun P Keegan, Molly E Droege iD, Aniruddha S Karve, Brandon Foreman, Devin Wakefield, Eric W Mueller, Kiranpal Sangha, Laura B Ngwenya, Joshua D Courter, Pankaj Desai und 1 weitere

Annals of Pharmacotherapy · 2024

DOI: 10.1177/10600280231202246 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Pharmacotherapy, 2024. Verfasst von Sarah Schuman Harlan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Services, Baptist Memorial Hospital, Memphis, TN, USA. Hauptthemen laut MEDLINE: Levetiracetam, Anticonvulsants, Brain Injuries, Traumatic, Seizures. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Clinical Pharmacy Critical Care Pharmacy and Research Network.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Drug pharmacokinetics (PK) are altered in neurocritically ill patients, and optimal levetiracetam dosing for seizure prophylaxis is unknown.

Objective

This study evaluates levetiracetam PK in critically ill patients with severe traumatic brain injury (sTBI) receiving intravenous levetiracetam 1000 mg every 8 (LEV8) to 12 (LEV12) hours for seizure prophylaxis.

Methods

This prospective, open-label study was conducted at a level 1 trauma, academic, quaternary care center. Patients with sTBI receiving seizure prophylaxis with LEV8 or LEV12 were eligible for enrollment. Five sequential, steady-state, postdose serum levetiracetam concentrations were obtained. Non-compartmental analysis (NCA) and compartmental approaches were employed for estimating pharmacokinetic parameters and projecting steady-state trough concentrations. Pharmacokinetic parameters were compared between LEV8 and LEV12 patients. Monte Carlo simulations (MCS) were performed to determine probability of target trough attainment (PTA) of 6 to 20 mg/L. A secondary analysis evaluated PTA for weight-tiered levetiracetam dosing.

Results

Ten male patients (5 LEV8; 5 LEV12) were included. The NCA-based systemic clearance and elimination half-life were 5.3 ± 1.2 L/h and 4.8 ± 0.64 hours. A one-compartment model provided a higher steady-state trough concentration for the LEV8 group compared with the LEV12 group (13.7 ± 4.3 mg/L vs 6.3 ± 1.7 mg/L; P = 0.008). Monte Carlo simulations predicted regimens of 500 mg every 6 hours, 1000 mg every 8 hours, and 2000 mg every 12 hours achieved therapeutic target attainment. Weight-tiered dosing regimens achieved therapeutic target attainment using a 75 kg breakpoint. Conclusion and Relevance: Neurocritically ill patients exhibit rapid levetiracetam clearance resulting in a short elimination half-life. Findings of this study suggest regimens of levetiracetam 500 mg every 6 hours, 1000 mg every 8 hours, or 2000 mg every 12 hours may be required for optimal therapeutic target attainment. Patient weight of 75 kg may serve as a breakpoint for weight-guided dosing to optimize levetiracetam therapeutic target attainment for seizure prophylaxis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LevetiracetamAnticonvulsantsBrain Injuries, TraumaticSeizuresHumansMaleProspective StudiesMiddle AgedAdultMonte Carlo MethodCritical IllnessPiracetamAgedHalf-Life

Stichwörter der Autor:innen

levetiracetampharmacodynamicspharmacokineticsseizure prophylaxistraumatic brain injury

Substanzen

LevetiracetamAnticonvulsantsPiracetam

Autor:innen und Institutionen

  • Department of Pharmacy Services, Baptist Memorial Hospital, Memphis, TN, USA.
  • Department of Clinical Pharmacy and Translational Science, University of Tennessee College of Pharmacy, Memphis, TN, USA.
  • Department of Pharmacy Services, UC Health-University of Cincinnati Medical Center, Cincinnati, OH, USA.
  • Division of Pharmacy Practice & Administrative Sciences, James L Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH, USA.
  • Esperion Therapeutics, Ann Arbor, MI, USA.
  • Division of Pharmaceutical Sciences, James L Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH, USA.

ORCID-Profile: Sarah Schuman Harlan, Molly E Droege, Christopher Droege

Förderung

  • Clinical Pharmacy Critical Care Pharmacy and Research Network

Zitieren

APA

Harlan, S. S., Philpott, C. D., Keegan, S. P., Droege, M. E., Karve, A. S., Foreman, B., Wakefield, D., Mueller, E. W., Sangha, K., Ngwenya, L. B., Courter, J. D., Desai, P., & Droege, C. (2024). Pharmacokinetics of Levetiracetam Seizure Prophylaxis in Severe Traumatic Brain Injury. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280231202246

Vancouver

Harlan SS, Philpott CD, Keegan SP, Droege ME, Karve AS, Foreman B, et al. Pharmacokinetics of Levetiracetam Seizure Prophylaxis in Severe Traumatic Brain Injury. Annals of Pharmacotherapy. 2024. doi:10.1177/10600280231202246

BibTeX
@article{Harlan2024,
  author = {Harlan, Sarah Schuman and Philpott, Carolyn D and Keegan, Shaun P and Droege, Molly E and Karve, Aniruddha S and Foreman, Brandon and Wakefield, Devin and Mueller, Eric W and Sangha, Kiranpal and Ngwenya, Laura B and Courter, Joshua D and Desai, Pankaj and Droege, Christopher},
  title = {Pharmacokinetics of Levetiracetam Seizure Prophylaxis in Severe Traumatic Brain Injury},
  journal = {Annals of Pharmacotherapy},
  year = {2024},
  doi = {10.1177/10600280231202246}
}
Kostenlos starten →